News of Note—Freenome bumps up series A to $72M; NxStage wins FDA nod for solo home dialysis


> Freenome raised an additional $7 million in series A funding, bringing its total to $72 million. In March, the liquid biopsy player raised $65 million in a round led by Andreessen Horowitz. Release

> The FDA cleared NxStage’s system for solo home dialysis. Patients may now perform hemodialysis at home, without a care partner, during waking hours. Release

> MedGenome bagged $30 million in series C financing—the company will ramp up biomarker discovery programs and further the development of its OncoPept suite of immunotherapy biomarker solutions. Release


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

Suggested Articles

The FDA approved a new device for people suffering from advanced heart failure who are not able to receive treatment from other devices.

Alcon has announced plans to launch its daily disposable contact lens in the U.S. made from a new material.

A mesh of integrated, electric sensors aims to track the earliest stages of tissue development and differentiation.